| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
Mesna targets acrolein and other urotoxic metabolites produced from the breakdown of chemotherapeutic agents like cyclophosphamide and ifosfamide. By binding to these reactive molecules, it prevents them from causing damage to the bladder epithelium, thus reducing the risk of hemorrhagic cystitis. It does not have a traditional receptor target.
|
|---|---|
| ln Vitro |
In dose illumination concentrations, mesna (1-1000 μM) decreases H2O2, HOCl, and OH; in experiments without cells, the corresponding IC50 values were 32, 21, and 305 μM.
In vitro, Mesna reacts with acrolein and other urotoxic metabolites to form stable, non-toxic compounds. This chemical interaction is the basis for its protective effect. Its mucolytic activity is also observed in vitro, as it can break down disulfide bonds in mucus. |
| ln Vivo |
Mesna (single intraperitoneal; 150 mg/kg) guards against brain stent injuries [1]. Mesna (200 mg/kg; single ip) reverses the glenoid function deficit caused by cisplatin [2]. Traumatic brain injury (TBI) was induced in adult male Wistar Albino rats weighing 250–350 g. The dose was 150 mg/kg, and the administration method was a single intraperitoneal injection. The results showed a decrease in tissue malondialdehyde levels. enhances superoxide dismutase and glutathione peroxidase activities. lowers nitric oxide, xanthine oxidase, and nitric oxide synthase levels. effectively shields brain cells from harm.
In vivo, Mesna is used as a chemoprotective agent to prevent hemorrhagic cystitis in patients receiving ifosfamide or cyclophosphamide. It is administered intravenously or orally. It is also used as a mucolytic agent. It has been studied for its potential to prevent contrast medium-induced nephrotoxicity. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for Mesna, as it functions as a chemical protectant rather than a receptor ligand. Its activity is assessed by measuring its ability to react with and neutralize urotoxic metabolites, such as acrolein, in chemical assays.
|
| Cell Assay |
In vitro cell-based assays for Mesna are not typically performed, as its mechanism of action is primarily chemical rather than cellular. However, its effects on cell viability and protection against acrolein-induced toxicity can be studied in cell culture models.
|
| Animal Protocol |
Animal/Disease Models: Adult male Wistar Albino rats (250-350 g) sustained traumatic brain injury (TBI) [1]
Doses: 150 mg/kg Route of Administration: Single intraperitoneal (ip) injection Experimental Results: diminished tissue malondialdehyde levels. Increases the activity of glutathione peroxidase and superoxide dismutase. Reduces levels of nitric oxide, nitric oxide synthase, and xanthine oxidase. Protects brain tissue well from damage. In vivo animal experiments for Mesna have been conducted in models of chemotherapy-induced hemorrhagic cystitis. The compound is typically administered to animals receiving cyclophosphamide or ifosfamide, and its protective effect on the bladder is assessed. |
| ADME/Pharmacokinetics |
Mesna is administered intravenously or orally. It is rapidly metabolized to its active form, mesna disulfide, which is reduced back to mesna in the kidneys. This renal conversion is important for its uroprotective effect. Its pharmacokinetics are well-characterized due to its clinical use.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Currently, there is no information regarding the clinical use of mesna during lactation. Because mesna is often used in combination with toxic drugs such as ifosfamide, the manufacturer recommends against breastfeeding during treatment and for one week after the last dose of mesna or ifosfamide. ◉ Effects on Breastfed Infants As of the revision date, no relevant published information was found. ◉ Effects on Lactation and Breast Milk As of the revision date, no relevant published information was found. Mesna is generally well-tolerated at therapeutic doses. Common side effects include nausea, vomiting, and headache. It has a favorable safety profile and is an important component of chemotherapy regimens to prevent bladder toxicity. |
| References |
|
| Additional Infomation |
Mesna is an organic sulfonic acid. Mesna is a thiol compound used to reduce the incidence of hemorrhagic cystitis caused by certain chemotherapy drugs. In the kidneys, mesna is converted to a free thiol compound, where it binds to and inactivates acrolein and other uremic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during excretion. (NCI04) A thiol compound that prevents urothelial toxicity by inactivating metabolites of antitumor drugs such as ifosfamide or cyclophosphamide. See also: ifosfamide; mesna (ingredient).
Mesna is a clinically approved drug used to prevent hemorrhagic cystitis in patients receiving ifosfamide or cyclophosphamide. It is also known as sodium 2-mercaptoethanesulfonate and is a sulfhydryl donor. It is available as an injectable and oral formulation. |
| Molecular Formula |
C2H5NAO3S2
|
|---|---|
| Molecular Weight |
164.18
|
| Exact Mass |
163.957
|
| CAS # |
19767-45-4
|
| Related CAS # |
3375-50-6 (parent cpd)
|
| PubChem CID |
23662354
|
| Appearance |
Off-white to gray solid powder
|
| Melting Point |
>240°C dec.
|
| LogP |
0.542
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
123
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XOGTZOOQQBDUSI-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C2H6O3S2.Na/c3-7(4,5)2-1-6;/h6H,1-2H2,(H,3,4,5);/q;+1/p-1
|
| Chemical Name |
sodium;2-sulfanylethanesulfonate
|
| Synonyms |
Filesna; Mesnum. US Mesnex. Foreign Ausobronc; mercaptoethane sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1522.72 mM)
H2O : ≥ 50 mg/mL (~304.54 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (609.09 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0909 mL | 30.4544 mL | 60.9088 mL | |
| 5 mM | 1.2182 mL | 6.0909 mL | 12.1818 mL | |
| 10 mM | 0.6091 mL | 3.0454 mL | 6.0909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Siplizumab for Sickle Cell Disease Transplant
CTID: NCT06078696
Phase: Phase 1/Phase 2 Status: Recruiting
Date: 2024-11-21
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
